AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
90.18
+0.15 (0.17%)
At close: Dec 5, 2025, 4:00 PM EST
90.40
+0.22 (0.24%)
After-hours: Dec 5, 2025, 7:00 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
4.83
Revenue / Employee
$625,694
Employees
92,900
Market Cap
280.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
AZN News
- 1 day ago - Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement - Business Wire
- 1 day ago - AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - Business Wire
- 3 days ago - Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension - Business Wire
- 9 days ago - Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies - CNBC
- 11 days ago - AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows - Benzinga
- 12 days ago - Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology - PRNewsWire
- 14 days ago - Why AstraZeneca Stock Bumped Higher Today - The Motley Fool
- 14 days ago - AstraZeneca to invest $2 billion as part of US manufacturing push - Reuters